Forecast Insight: Hepatitis B - Baraclude and Viread Set to Thrive in the Face of Limited Competition Now Available at Reportsandreports
In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009.
View full press release